Inspira Technologies has received its first order for the INSPIRA ART100 systems from Glo-Med Networks, marking a significant milestone in its expansion plan within the US market.

The initial order includes five units expected to be shipped in the fourth quarter of this year, with the potential for an additional 20 systems subject to further agreement.

The INSPIRA ART100 systems are part of the company’s strategy to penetrate the $19bn mechanical ventilator market with its next-generation technology.

The systems are designed to potentially replace mechanical ventilation, offering an advanced solution.

These units are intended for use in US hospitals.

Inspira plans to provide hospitals with an option for the integrated HYLA Blood Sensor and INSPIRA ART (Gen 2) devices, pending the completion of product development and regulatory approvals.

Inspira director, president and co-founder Joe Hayon said: “We continue to develop the breakthrough technologies of tomorrow.

“The INSPIRA ART100 is our first and important step in building the INSPIRA market presence and position in preparation for the INSPIRA ART (Gen 2), which we believe has the potential to provide a new clinical solution with a potentially different intent of use for the mega life support and mechanical ventilation market.”

In March 2024, Inspira said it was seeking approval for its INSPIRA ART100 device to enter the South East Asia and South American markets.

The application for the device, which is intended for patients undergoing cardiopulmonary bypass procedures, was submitted to AMAR, the Israeli Ministry of Health’s medical device regulation unit.